SYNGENE Stock Overview
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally.
SYNGENE passed our risk checks.
Syngene International Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹568.25|
|52 Week High||₹700.00|
|52 Week Low||₹510.05|
|1 Month Change||6.82%|
|3 Month Change||-2.69%|
|1 Year Change||-2.72%|
|3 Year Change||74.04%|
|5 Year Change||140.86%|
|Change since IPO||265.96%|
Recent News & Updates
These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|SYNGENE||IN Life Sciences||IN Market|
Return vs Industry: SYNGENE exceeded the Indian Life Sciences industry which returned -12.1% over the past year.
Return vs Market: SYNGENE underperformed the Indian Market which returned -0.9% over the past year.
|SYNGENE Average Weekly Movement||5.1%|
|Life Sciences Industry Average Movement||6.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in IN Market||9.9%|
|10% least volatile stocks in IN Market||4.5%|
Stable Share Price: SYNGENE is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: SYNGENE's weekly volatility (5%) has been stable over the past year.
About the Company
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company offers discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also provides exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services.
Syngene International Fundamentals Summary
|SYNGENE fundamental statistics|
Is SYNGENE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SYNGENE income statement (TTM)|
|Cost of Revenue||₹7.49b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||9.97|
|Net Profit Margin||15.20%|
How did SYNGENE perform over the long term?See historical performance and comparison
0.09%Current Dividend Yield
Does SYNGENE pay a reliable dividends?See SYNGENE dividend history and benchmarks
|Syngene International dividend dates|
|Ex Dividend Date||Jun 30 2022|
|Dividend Pay Date||Aug 19 2022|
|Days until Ex dividend||2 days|
|Days until Dividend pay date||52 days|
Does SYNGENE pay a reliable dividends?See SYNGENE dividend history and benchmarks
Is SYNGENE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SYNGENE?
Other financial metrics that can be useful for relative valuation.
|What is SYNGENE's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SYNGENE's PE Ratio compare to its peers?
|SYNGENE PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
DIVISLAB Divi's Laboratories
TARSONS Tarsons Products
540701 Dishman Carbogen Amcis
524394 Vimta Labs
SYNGENE Syngene International
Price-To-Earnings vs Peers: SYNGENE is expensive based on its Price-To-Earnings Ratio (57.1x) compared to the peer average (47.7x).
Price to Earnings Ratio vs Industry
How does SYNGENE's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
Price-To-Earnings vs Industry: SYNGENE is expensive based on its Price-To-Earnings Ratio (57.1x) compared to the Indian Life Sciences industry average (33x)
Price to Earnings Ratio vs Fair Ratio
What is SYNGENE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||57.1x|
|Fair PE Ratio||29.5x|
Price-To-Earnings vs Fair Ratio: SYNGENE is expensive based on its Price-To-Earnings Ratio (57.1x) compared to the estimated Fair Price-To-Earnings Ratio (29.5x).
Share Price vs Fair Value
What is the Fair Price of SYNGENE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SYNGENE (₹568.25) is trading above our estimate of fair value (₹249.78)
Significantly Below Fair Value: SYNGENE is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: SYNGENE is poor value based on its PEG Ratio (2.5x)
Discover undervalued companies
How is Syngene International forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYNGENE's forecast earnings growth (22.6% per year) is above the savings rate (6.7%).
Earnings vs Market: SYNGENE's earnings (22.6% per year) are forecast to grow faster than the Indian market (17.4% per year).
High Growth Earnings: SYNGENE's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SYNGENE's revenue (16% per year) is forecast to grow faster than the Indian market (11.5% per year).
High Growth Revenue: SYNGENE's revenue (16% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SYNGENE's Return on Equity is forecast to be low in 3 years time (16.3%).
Discover growth companies
How has Syngene International performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYNGENE has high quality earnings.
Growing Profit Margin: SYNGENE's current net profit margins (15.2%) are lower than last year (18.5%).
Past Earnings Growth Analysis
Earnings Trend: SYNGENE's earnings have grown by 8% per year over the past 5 years.
Accelerating Growth: SYNGENE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SYNGENE had negative earnings growth (-2.2%) over the past year, making it difficult to compare to the Life Sciences industry average (47.7%).
Return on Equity
High ROE: SYNGENE's Return on Equity (12%) is considered low.
Discover strong past performing companies
How is Syngene International's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SYNGENE's short term assets (₹22.1B) exceed its short term liabilities (₹12.3B).
Long Term Liabilities: SYNGENE's short term assets (₹22.1B) exceed its long term liabilities (₹10.4B).
Debt to Equity History and Analysis
Debt Level: SYNGENE has more cash than its total debt.
Reducing Debt: SYNGENE's debt to equity ratio has reduced from 58.9% to 23.9% over the past 5 years.
Debt Coverage: SYNGENE's debt is well covered by operating cash flow (73.5%).
Interest Coverage: SYNGENE's interest payments on its debt are well covered by EBIT (17.9x coverage).
Discover healthy companies
What is Syngene International current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: SYNGENE's dividend (0.087%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.43%).
High Dividend: SYNGENE's dividend (0.087%) is low compared to the top 25% of dividend payers in the Indian market (1.89%).
Stability and Growth of Payments
Stable Dividend: SYNGENE is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: SYNGENE is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: SYNGENE is not paying a notable dividend for the Indian market.
Cash Payout to Shareholders
Cash Flow Coverage: SYNGENE is not paying a notable dividend for the Indian market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jonathan Hunt (52 yo)
Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...
CEO Compensation Analysis
Compensation vs Market: Jonathan's total compensation ($USD832.63K) is about average for companies of similar size in the Indian market ($USD642.44K).
Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.
Experienced Management: SYNGENE's management team is seasoned and experienced (6.3 years average tenure).
Experienced Board: SYNGENE's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SYNGENE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Syngene International Limited's employee growth, exchange listings and data sources
- Name: Syngene International Limited
- Ticker: SYNGENE
- Exchange: NSEI
- Founded: 1993
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹225.893b
- Shares outstanding: 397.17m
- Website: https://www.syngeneintl.com
Number of Employees
- Syngene International Limited
- Biocon SEZ, Biocon Park,
- Plot No. 2 & 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.